Results from the Phase III CONVOKE trial (NCT05838625) showed that CT-155 demonstrated a favorable safety profile consistent ...

Radella Pharmaceuticals reveals promising Phase 1b trial results for MD-18, showcasing significant weight loss and ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Access inequity is driven by operational and bureaucratic challenges, affecting both low-income and developed nations, beyond ...

GLP-1 medication users must consult physicians before surgery to mitigate anesthesia risks and ensure safe pre-operative ...

The talks are a result of the MFN order, which seeks to make US drug prices match lower prices in international markets.

Gene Mack, CEO of Gain Therapeutics, outlines the company’s strategic approach to advancing GT-02287 through potential collaborations and financing options as they await critical Parkinson’s disease ...

In May, Pfizer CEO Dr. Albert Bourla defended previous comments HHS officials made about mRNA vaccines. 2 At the time, he called mRNA vaccines the most utilized vaccines in human history. He cited the ...

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 ...

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

XtalPi and DoveTree collaborate on a groundbreaking $6 billion drug discovery partnership, merging AI technology with ...

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?